BioSpace News Archive

Drug Development

uniQure Begins First-in-Human Gene Therapy Trials for Huntington’s Disease

In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.

August 4, 2020
·
4 min read
·
Gail Dutton
Pharm Country

Regeneron’s Antibody Cocktail Prevents and Treats COVID-19 in Lab Animals

The studies were run on a total of 36 rhesus macaques and 50 hamsters. The company is careful to caution that positive animal studies do not guarantee success in humans.

August 4, 2020
·
3 min read
·
Mark Terry
Biotech Bay

IgGenix Launches with $10 Million to Develop Therapeutics for Severe Allergies

Startup IgGenix, Inc. emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions.

August 4, 2020
·
3 min read
·
Alex Keown
Policy

Biopharma Update on the Novel Coronavirus: August 5

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.

August 4, 2020
·
5 min read
·
BioSpace Editorial Staff
Drug Development

As Clinical Trials Go Digital, Complexity Grows Along with the Risk to Data Integrity

Data security risks are growing as more and more clinical trials embrace telemedicine and other digital technologies.

August 4, 2020
·
4 min read
·
Gail Dutton
Policy

FDA Issues CRL for DBV Technologies’ Viaskin Peanut Allergy Patch

In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.

August 4, 2020
·
2 min read
·
Alex Keown
Business

AbbVie Terminates Alzheimer’s Pact with Voyager Therapeutics

Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership has come to an end after AbbVie terminated the agreement.

August 4, 2020
·
2 min read
·
Alex Keown
Pharm Country

Merck and Hanmi Ink $870 Million NASH Deal

Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).

August 4, 2020
·
2 min read
·
Mark Terry
Drug Development

New Research Sheds Light on the Temporary Loss of Smell Stemming from COVID-19

According to a study published in the journal Science Advances on July 24, an international team of researchers led by neuroscientists at Harvard Medical School has uncovered which olfactory cell types are most vulnerable to infection by SARS-CoV-2, which causes COVID-19.

August 4, 2020
·
3 min read
·
Krystle Vermes
Business

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program

University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper-inflammatory response to serum from severe COVID-19 patients

August 4, 2020
·
17 min read